

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

ANNOUNCEMENT
ISSUANCE OF FILING NOTICE BY THE CSRC IN RESPECT OF THE
COMPANY'S PROPOSED H SHARE FULL CIRCULATION

This announcement is made by Qyuns Therapeutics Co., Ltd. (the "**Company**") on a voluntary basis.

Reference is made to the announcement of the Company dated October 28, 2024 (the "**Announcement**") in relation to the acceptance by the China Securities Regulatory Commission (the "**CSRC**") of the Company's application to the CSRC for the proposed implementation of H share full circulation on behalf of certain shareholders of the Company (the "**Application**"). Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Company is pleased to announce that, the Company has received a filing notice dated January 20, 2025 (the "**Filing Notice**") issued by the CSRC regarding the Application. Pursuant to the Filing Notice, the conversion of 17,322,400 domestic shares (the "**Domestic Shares**") issued by the Company into H shares and the listing of such shares on the Stock Exchange (the "**Conversion and Listing**") have been filed with the CSRC. If the share conversion has not been completed within 12 months from the date of the issuance of the Filing Notice and it is intended to continue to be, an updated filing to the CSRC will be required.

As at the date of this announcement, details of the implementation plan for the Conversion and Listing have not been finalized. The Completion of the Conversion and Listing is also subject to other relevant procedures as required by the CSRC, the Stock Exchange and other relevant domestic and overseas regulatory authorities. The Company will make further announcements in accordance with the Listing Rules as and when appropriate in relation to the progress of the Conversion and Listing. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan

Chairman of the Board and Executive Director

Hong Kong, January 21, 2025

As at the date of this announcement, the board of directors of the Company comprises Mr. Qiu Jiwan as chairman and executive director, Mr. Wu Yiliang and Mr. Lin Weidong as executive directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive directors.